Heart Test Laboratories, Inc. (HSCS)

NASDAQ: HSCS · IEX Real-Time Price · USD
0.870
+0.089 (11.37%)
At close: Jan 27, 2023, 3:52 PM
0.890
+0.020 (2.30%)
After-hours: Jan 27, 2023, 4:56 PM EST
11.37%
Market Cap 7.27M
Revenue (ttm) 10,089
Net Income (ttm) -6.67M
Shares Out 8.35M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,805
Open 0.761
Previous Close 0.781
Day's Range 0.761 - 0.922
52-Week Range 0.710 - 6.000
Beta n/a
Analysts Buy
Price Target 5.61 (+544.83%)
Earnings Date Mar 16, 2023

About HSCS

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas. [Read more]

Industry Medical Devices
Sector Healthcare
CEO Mr. Andrew Simpson
Employees 13
Stock Exchange NASDAQ
Ticker Symbol HSCS
Full Company Profile

Financial Performance

In 2022, HSCS's revenue was $14,373, a decrease of -43.86% compared to the previous year's $25,604. Losses were -$4.83 million, 96.9% more than in 2021.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for HSCS stock is "Buy." The 12-month stock price forecast is $5.61, which is an increase of 544.83% from the latest price.

Price Target
$5.61
(544.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th

Southlake, Texas, Jan. 23, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on January 20th, 2023, by HeartSciences (NASDAQ: HSCS; HSCSW), please note that in the second paragraph ...

4 days ago - GlobeNewsWire

HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th

Southlake, Texas, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on ...

1 week ago - GlobeNewsWire

HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive

Southlake, TX, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on sav...

3 weeks ago - GlobeNewsWire

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results

Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmis...

1 month ago - GlobeNewsWire

HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms

Southlake, Texas, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on ...

2 months ago - GlobeNewsWire

HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022

Southlake, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on ...

2 months ago - GlobeNewsWire

HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022

Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on...

2 months ago - GlobeNewsWire

HeartSciences' MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events

Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification Independent study demonstrates novel AI-ECG algorithm could prov...

2 months ago - GlobeNewsWire

HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG

Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Patent builds on previously granted U.S. patent as well as ...

3 months ago - GlobeNewsWire

HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction

Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences' MyoVista Issuance of new reimbursement-...

3 months ago - GlobeNewsWire

HeartSciences to Present at the LD Micro Main Event XV on October 26th

Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS) (NASDAQ: HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known a...

3 months ago - Newsfile Corp

HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th

SOUTHLAKE, TX / ACCESSWIRE / October 6, 2022 / Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on applyi...

4 months ago - Accesswire

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results

Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista®

4 months ago - GlobeNewsWire

HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology to...

4 months ago - GlobeNewsWire

HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on...

5 months ago - GlobeNewsWire

HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results

MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year

6 months ago - GlobeNewsWire

HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th

Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW)  (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also kn...

7 months ago - GlobeNewsWire

Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing

SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative ...

8 months ago - GlobeNewsWire